Helmy Eltoukhy

Helmy Eltoukhy is the Co-CEO of Guardant Health. Helmy has a long history of working in the field of sequencing and related technologies. Helmy started their career at Aurum Capital Management as an Analyst/Programmer. Helmy then moved to Stanford Genome Technology Center as a Postdoctoral Fellow, researching novel assays and detection modalities for nucleic acid analysis. In 2006, they became the President & CEO of Avantome, where they were responsible for Financing, Corporate Development, Business Development, Operations, Research, Technology Development, Commercial Operations, and Branding. In 2007, they joined Illumina as Sr. Director, Advanced Technology Group. Helmy worked on Novel Sequencing Biochemistry R&D, Novel Sensor/Detection for Sequencing R&D, Long read sequencing R&D, and Novel Sequencing Instrument Architecture R&D. Helmy also worked on Large Scale Integration for Genetic Analysis and Semiconductor-based Genetic Analysis Systems. In 2012, they left Illumina to co-found Guardant Health, where they are currently Co-CEO.

Helmy Eltoukhy has a PhD in Electrical Engineering from Stanford University. Helmy also has an MS in Electrical Engineering from Stanford University, and a BS in Electrical Engineering from Stanford University.

Andy Ament - SVP, Operations, Kumud Kalia - CIO, and Darl Moreland - SVP, Regulatory & Quality report to Helmy Eltoukhy.